Brand and Other Names:Brovana, Erdotin
- Classes: Beta2 Agonists
Dosing & Uses
Dosage Forms & Strengths
Chronic Obstructive Pulmonary Disease
15 mcg inhaled via nebulization twice daily (AM & PM)
Not to exceed 30 mcg/day
Dose adjustment not necessary
Use caution; systemic drug exposure prolonged; dose adjustment not necessary
Saftety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Back pain (6%)
Chest pain (7%)
Flu syndrome (3%)
Leg cramps (4%)
Lung disorder (2%)
Peripheral edema (3%)
Black Box Warnings
Long-acting beta2-adrenergic agonists (LABAs), such as arformoterol, may increase the risk of asthma-related deaths; therefore, when treating patients with asthma, this drug should only be used as additional therapy for patients not adequately controlled on other asthma controller medications (eg, low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with 2 maintenance therapies, including LABAs
Because of this risk, use of LABAs for the treatment of asthma without a concomitant long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated
Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (eg, discontinue LABA) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid
Do not use LABAs if asthma is adequately controlled on low or medium dose inhaled corticosteroids
Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients; for pediatric and adolescent patients with asthma who require addition of a LABA to an inhaled corticosteroid, a fixed-dose combination product containing both an inhaled corticosteroid and LABA should ordinarily be considered to ensure adherence with both drugs
Safety and efficacy of arformoterol in patients with asthma not established
Hypersensitivity to arformoterol or formoterol, or any ingredients
Concurrency with other long-acting beta2-agonists
Treatment of asthma without a concomitant long-term asthma control medication, such as an inhaled corticosteroid
May cause paradoxical bronchospasm
Long-acting beta2-agonists may increase risk of asthma-related death
Use caution in cardiovascular disorder (arrhythmias, HTN, CAD), hepatic impairment, hypokalemia, thyrotoxicosis, seizure disorders
Risk of hypokalemia (usu transient not requiring supplementation)
Combined with asthma controller medication (e.g., inhaled corticosteroid)
Use only if not adequately controlled by asthma controller medications
Use only for shortest duration of time
Beta2-agonists may increase serum glucose (use with caution in patients with diabetes)
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Not known if excreted in breast milk, use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Long-acting beta2-agonist, R,R-enantiomer of racemic formoterol; relaxes bronchial smooth muscle by acting selectively on beta2-receptors
Excretion: Urine (67%); feces (22%)
Onset: 7-20 min
Peak plasma time: 0.5-3hr
Peak Plasma: 4.3 pg/mL
AUC: 34.5 pg.hr/mL
Protein Bound: 52-65%
Metabolism: uridine diphosphoglucuronosyltransferases (glucuronidation), CYP2D6, CYP2C19 (O-demethylation)
Renal Clearance: 8.9 L/hr
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs